Compare YieldMax AMD Option Income Strategy ETF (AMDY) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax AMD Option Income Strategy ETF vs Novo Nordisk A/S — how do they compare? YieldMax AMD Option Income Strategy ETF trades at $53.74, while Novo Nordisk A/S trades at $49.22 (market cap $216.71B). The key difference: Novo Nordisk A/S pays a 3.64% dividend while YieldMax AMD Option Income Strategy ETF pays none, and YieldMax AMD Option Income Strategy ETF is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.
| AMDY | NVO | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $59.52 | $71.70 |
52-Week Low | $29.80 | $35.29 |
Market Cap | — | $216.71B |
Enterprise Value | — | $235.67B |
Dividend Yield | — | 3.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMDY trades at $55.56, up 2.04% today, with a bullish technical signal from moving averages and neutral oscillators. The ETF shows strong weekly dividend distributions but lacks traditional valuation metrics. Recent news highlights its high-yield strategy and associated risks of NAV erosion, with support at $54 and resistance at $56.
The outlook is mixed: high income appeals, but structural risks and analyst caution suggest volatility. Investors must weigh yield sustainability against potential capital depreciation, with entry timing critical for long-term viability.
Novo Nordisk (NVO) trades at $49.48, up 1.23% today, with a bullish technical signal from moving averages and strong fundamentals including a 37.2% net income margin and 71.4% ROE. Recent earnings beats in Q3 2025-Q1 2026 highlight operational strength, while cash flow remains positive at $10.81B in 2025. The stock benefits from GLP-1 drug leadership, with oral Wegovy driving market expansion amid competitive pressures.
Outlook is positive with analyst consensus at 57.9% buy ratings, but risks include prescription slowdown concerns and rising debt-to-asset ratio to 22.54 in 2025. Investment appeal lies in robust profitability and growth in obesity/diabetes treatments, though investors should monitor competition and execution on guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About YieldMax AMD Option Income Strategy ETF
AMDY is an active ETF that seeks to generate weekly income by selling call options on AMD stock. It aims to provide investors with high yield while maintaining exposure to the price movements of Advanced Micro Devices.
Read more on AMDY →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
